Anisomycin_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries
Data Sheet
BIOLOGICAL ACTIVITY:
Anisomycin is a pyrrolidine antibiotic, acts as an anti–fungal antibiotic which inhibits Protein Synthesis, also is a potent activator of SAPKs/JNKs.
Target: antibiotic
in vitro: Anisomycin inhibits EAC cell proliferation in concentration–dependent manner. [2] Anisomycin (3 μM) decreases protein synthesis in MDA16 and MDA–MB–468 cells, and reduces colony formation by MDA–MB–468 cells. Anisomycin causes an increase in the number of apoptotic cells in MDA–MB–468 cultures, but not in MDA16 cultures. Anisomycin actives JNK phosphorylation in MDA–MB–468 cells.[3]
in vivo: Peritumoral administration of anisomycin (5 mg/kg) significantly suppresses Ehrlich ascites carcinoma (EAC) growth resulting in the survival of approximately 60% of the mice 90 days after EAC inoculation. [2]
PROTOCOL (Extracted from published papers and Only for reference)
Cell assay [2]
For the assay, EAC cells are plated in 96–well plates at a density of 10,000 cells/well/200 μL of medium. The cells are treated with the different concentrations of Anisomycin for 48 h. Adriamycin (500 ng/mL) is used as a positive control. 0.5 mg/mL of MTT is added to each well. 4 h later, the formazan product of MTT reduction is dissolved in DMSO, and absorbance is measured at 570 nm using a Model 680 microplate reader.
Animal administrattion [1]
The 47 young, adult male Sprague Dawley rats weighing between 200 and 350 g. All rats were housed individually in 47 × 25 × 20.5cm polycarbonate cages for the duration of the experiment with a 12 h light/dark cycle. Anisomycin (100 μg/μl dissolved in 10 N HCl and brought to volume with PBS) was used for dorsal hippocampus infusions. On day 3 of training, animals were randomly assigned to one of the three conditions: Anisomycin (100 μg/μl dissolved in 10 N HCl and brought to volume with PBS), or a vehicle control group (PBS). Solutions were infused into both dorsal hippocampal hemispheres through 26 gauge stainless steel internal cannulae attached to a 10 μl Hamilton syringe with polyethylene tubing at a rate of 0.5 μl/min for 2 min (total infusion volume of 1 μl per hemisphere) using a double infusion pump. Internal infusion cannulae were left in the guide cannulae for one additional minute to allow for diffusion of the drug out of the cannulae. Infusions were performed on awake animals that were lightly restrained by an experimenter. Behavioral testing occurred 30 min following the start of the infusion. This corresponds to the time period of maximal neural suppression for Anisomycin.
References:
Product Name:
Anisomycin Cat. No.:
HY-18982CAS No.:
22862-76-6Molecular Formula:
C 14H 19NO 4Molecular Weight:
265.30Target:
Bacterial; JNK Pathway:
Anti–infection; MAPK/ERK Pathway Solubility:
10 mM in DMSO
[1]. Dubue JD, et al. Intrahippocampal Anisomycin Impairs Spatial Performance on the Morris Water Maze. J Neurosci. 2015 Aug 5;35(31):11118–11124.
[2]. You P, et al. In vitro and in vivo evaluation of anisomycin against Ehrlich ascites carcinoma. Oncol Rep. 2013, 29(6), 2227–2236.
[3]. Monaghan D, et al. Inhibition of protein synthesis and JNK activation are not required for cell death induced by anisomycin andanisomycin analogues. Biochem Biophys Res Commun. 2014 Jan 10;443(2):761–767.
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。